US pharma giant to invest 280 million euros in Irish manufacturing
Merck & Co (NYSE: MRK) has pledged to create 330 new jobs and invest 280 million euros ($314 million) over the next three years at two of its Irish manufacturing sites.
The new jobs, to be created in Carlow and Cork, are as a result of increased global demand for the US pharma giant’s medicines and vaccines produced in Ireland, while the investment will see both sites expand production facilities and capacity to meet that demand.
Merck’s County Cork site is a facility for the development, testing and manufacturing of biologics, specializing in the fermentation, purification and sterile filling of biotech products. More than 200 new hires will be needed to work on treatments including medicines for lung cancer, melanoma, hepatitis C and rheumatoid arthritis.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze